Hansoh Pharmaceutical (03692) Announces B7-H3 Targeted Antibody-Drug Conjugate HS-20093 Granted Breakthrough Therapy Designation for Osteosarcoma

Hansoh Pharma (03692) announced that on February 25, 2025, HS-20093 Injection, a self-developed B7-H3-targeting antibody-drug conjugate (ADC) by the group, was approved by the National Medical Products Administration (NMPA) of China for inclusion in the breakthrough therapy designation. The proposed indication is for the treatment of osteosarcoma patients who have progressed after at least two prior lines of therapy.

HS-20093 is a B7-H3-targeted ADC covalently linked by a fully human anti-B7-H3 monoclonal antibody and a topoisomerase inhibitor (TOPOi) payload. It is currently undergoing multiple clinical studies in China for the treatment of lung cancer, sarcoma, head and neck cancer, and other solid tumors, with the highest stage of research being Phase III clinical trials. On November 1, 2024, HS-20093 was granted Breakthrough Therapy Designation by the NMPA for the treatment of extensive-stage small cell lung cancer (ES-SCLC) that has progressed after standard first-line treatment (platinum-based doublet chemotherapy combined with immunotherapy).